Posted by Michael Wonder on 25 Jun 2024
Ezharmia approved in Japan as first dual EZH1 and EZH2 inhibitor therapy for patients with peripheral T-cell lymphoma
24 June 2024 - Approval based on VALENTINE-PTCL01 results showing a clinically meaningful objective response rate of 43.7% in patients with relapsed or refractory peripheral T-cell lymphoma.
Daiichi Sankyo’s Ezharmia (valemetostat tosilate) has been approved in Japan for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma.
